Altimmune (ALT) Stock Price, News & Analysis

Company Overview

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland.

Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.

Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine. The company was formed in 2017 through a merger between Altimmune and PharmAthene.

Key Stats

• Today's Range: $1.90 to $2.13
• 50-Day Range: $1.94 to $3.42
• 52-Week Range: $1.90 to $6.44
• Volume: 3.99 million shs
• Average Volume: 3.55 million shs
• Market Capitalization: $377.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.33
• Consensus Rating: Moderate Buy

Altimmune Stock Analysis - MarketRank™

Altimmune scored higher than 54% of companies evaluated by MarketBeat, and ranked 541st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Altimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Altimmune has a consensus price target of $14.33, representing about 638.8% upside from its current price of $1.94.

Amount of Analyst Coverage

Altimmune has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Altimmune are expected to grow in the coming year, from ($0.58) to ($0.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Altimmune is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Altimmune is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Altimmune has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.01% of the float of Altimmune has been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 12.16, which indicates bearish sentiment.

Change versus previous month

Short interest in Altimmune has recently decreased by 0.24%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Altimmune does not currently pay a dividend.

Dividend Growth

Altimmune does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.38

News Sentiment

Altimmune has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Altimmune this week, compared to 5 articles on an average week.

Search Interest

16 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Altimmune insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of Altimmune is held by insiders.

Percentage Held by Institutions

78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 11/10/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALT
• CIK: 1326190
• Web: altimmune.com
• Phone: (240) 654-1450
• Fax: 410-269-2601
• Employees: 57
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Altimmune: $14.33
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +638.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.09 million
• Net Margins: N/A
• Pretax Margin: -296,000.00%
• Return on Equity: -31.41%
• Return on Assets: -26.96%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 26.78
• Quick Ratio: 26.78

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 9,434.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.99 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 194,520,000
• Free Float: 191,406,000
• Market Cap: $377.37 million
• Optionable: Optionable
• Beta: 0.16